etentamig subcutaneous (ABBV-383 SC) / AbbVie - LARVOL DELTA

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: AbbVie | Trial completion date: Feb 2027 ➔ Dec 2027

Adverse events • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Phase Ib Study Investigating the Safety, Pharmacokinetics, and Efficacy of Subcutaneous Administration of ABBV-383 in Patients With Relapsed/Refractory Multiple Myeloma (IMW 2024) - P1 | "The primary objectives are to characterize the safety, tolerability, and pharmacokinetics (PK) of ABBV-383 after single subcutaneous (SC) administration and IV administration thereafter (part 1) and after SC administration until the end of treatment (part 2), and to determine the dose of ABBV-383 that would yield exposures comparable to that of the IV administration. n/a"

Clinical • P1 data • PK/PD data • Hematological Malignancies • Multiple Myeloma • Oncology

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=55 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jun 2024

Adverse events • Enrollment open • Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology